News Archive
Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.
New research conducted by Medibank 24/7 Health Advice Line reveals the majority (97%) of Australians do not know all the major symptoms of diabetes or how many types there are, despite it affecting 3.6 million people nationwide and costing the economy $6 billion per year.
Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that the United States Patent and Trademark Office has issued Patent No. 7,982,036, "4,6-Disubstituted Pyrimidines Useful as Kinase Inhibitors."
We asked Dr. Lion Shahab, one of the UK's leading experts on e-cigarettes and smoking, to provide the truth about the safety of vaping and for his advice to people giving up cigarettes this World Cancer Day.
› Verified 5 days ago